SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
4.080
-0.140 (-3.32%)
Oct 9, 2026, 4:00 PM EDT - Market closed
SCYNEXIS Revenue
SCYNEXIS had revenue of $235.00K in the quarter ending June 30, 2026, a decrease of -82.77%. This brings the company's revenue in the last twelve months to $17.77M, up 445.46% year-over-year. In the year 2025, SCYNEXIS had annual revenue of $41.20M with 449.95% growth. That makes SCYNEXIS the 34,019th largest company in the world by revenue and 4,477th in the United States.
Revenue (ttm)
$17.77M
Revenue Growth
+445.46%
P/S Ratio
2.11
Revenue / Employee
$1,067,556
Employees
18
Market Cap
40.59M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.20M | 33.71M | 449.95% |
| Dec 31, 2024 | 7.49M | -272.79M | -97.33% |
| Dec 31, 2023 | 280.28M | 270.10M | 2,652.72% |
| Dec 31, 2022 | 10.18M | -16.14M | -61.32% |
| Dec 31, 2021 | 26.33M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 121.00K | -136.00K | -52.92% |
| Dec 31, 2018 | 257.00K | - | - |
| Dec 31, 2017 | 257.00K | - | - |
| Dec 31, 2016 | 257.00K | - | - |
| Dec 31, 2015 | 257.00K | -999.00K | -79.54% |
| Dec 31, 2014 | 1.26M | -15.60M | -92.55% |
| Dec 31, 2013 | 16.86M | 20.00K | 0.12% |
| Dec 31, 2012 | 16.84M | -9.62M | -36.35% |
| Dec 31, 2011 | 26.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| InterCure | 84.76M |
| Rockwell Medical | 69.39M |
| Aytu BioPharma | 57.57M |
| Universe Pharmaceuticals INC | 17.74M |
| Zhengye Biotechnology Holding | 16.64M |
| China Pharma Holdings | 3.91M |
| TherapeuticsMD | 3.27M |
| Optimi Health | 123.70K |
SCYX News
- 5 days ago - Scynexis completes study of SCY-770 - TheFly
- 5 days ago - SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - GlobeNewsWire
- 13 days ago - Brookline says BARDA contract a major positive for Scynexis’ SCY-247 program - TheFly
- 13 days ago - Scynexis awarded contract by BARDA contract, providing up to $214M in funding - TheFly
- 13 days ago - SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 - GlobeNewsWire
- 19 days ago - Scynexis appoints Burke to Board of Directors - TheFly
- 19 days ago - SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D. - GlobeNewsWire
- 26 days ago - SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development - GlobeNewsWire